Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/1/00 → 1/1/00 |
Funding
- Pfizer, Inc.: $10,766.15
A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT BNT162b2 RNA -BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDREN
- Rupp, Richard (PI)
Project: Other project